Equipotent doses to switch from high doses of opioids to transdermal buprenorphine
- 23 December 2008
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 17 (6) , 715-718
Abstract
The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120–240 mg of oral morphine or 50–100 µg of TD fentanyl, reporting adequate pain and symptom control. Patients receiving daily stable doses of opioids for more than 6 days, with no more than two doses of oral morphine (20 and 40 mg, respectively) as needed, were switched to TD BUP using a fentanyl–BUP ratio of 0.6:0.8 and an oral morphine–BUP ratio of 70:1. Opioid doses, pain and symptom intensity, global satisfaction, and number of breakthrough medication were recorded before switching (T0), 3 days after (T3), and 6 days after (T6). Eleven patients were recruited in a period of 1 year, and data were complete for ten patients. The mean age was 61.6 (SD 9.5), and five patients were males. No significant changes in pain and symptom intensity were found, except improvement in reported constipation (p = 0.014), as well as in global satisfaction with the analgesic treatment. No significant changes in breakthrough pain medication were observed. The results of this study suggest that stable patients receiving relatively high doses of oral morphine or TD fentanyl could be safely switched to TD BUP, by using a ratio of 70:1 and 0.6:0.8, respectively, maintaining the same level of analgesia.Keywords
This publication has 10 references indexed in Scilit:
- Challenging the equipotency calculation for transdermal buprenorphine: four case studiesInternational Journal Of Clinical Practice, 2007
- Switching from Transdermal Drugs: An Observational “N of 1” Study of Fentanyl and BuprenorphineJournal of Pain and Symptom Management, 2007
- Opioid Rotation from High‐Dose Morphine to Transdermal Buprenorphine (Transtec®) in Chronic Pain PatientsPain Practice, 2007
- Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patientsSupportive Care in Cancer, 2006
- Safety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal BuprenorphineJournal of Pain and Symptom Management, 2006
- Buprenorphine in cancer painSupportive Care in Cancer, 2005
- Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort studyClinical Therapeutics, 2005
- Broad analgesic profile of buprenorphine in rodent models of acute and chronic painEuropean Journal of Pharmacology, 2005
- Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trialClinical Therapeutics, 2003
- Morphine and alternative opioids in cancer pain: the EAPC recommendationsBritish Journal of Cancer, 2001